Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug [Yahoo! Finance]
Neumora Therapeutics, Inc. (NMRA)
Company Research
Source: Yahoo! Finance
allosteric modulator (PAM) of the M4 muscarinic receptor, for treating some types of neuropsychiatric disorders. The regulatory body placed the clinical hold after pre-clinical data showed convulsions in rabbits following treatment with NMRA-266. Shares of NMRA were down 17.5% on Apr 15 following the announcement of the news. Following the FDA's clinical hold, the phase I single ascending dose/multiple ascending dose study investigating NMRA-266 has been paused. However, around 30 participants who were already dosed in the above mentioned early-stage study have not experienced any evidence of convulsions as of now. The company is currently working closely with the FDA to resolve the clinical hold. Shares of Neumora have plunged 34.4% so far this year compared with the industry's decline of 7.9%. Image Source: Zacks Investment Research NMRA-266 is being developed as a treatment for schizophrenia and other neuropsychiatric disorders. In March 2024, Neumora announced that
Show less
Read more
Impact Snapshot
Event Time:
NMRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NMRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NMRA alerts
High impacting Neumora Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NMRA
News
- Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- Neumora Therapeutics to Participate in Upcoming Conferences in May [Yahoo! Finance]Yahoo! Finance
- Neumora Therapeutics to Participate in Upcoming Conferences in MayGlobeNewswire
- We're Hopeful That Neumora Therapeutics (NASDAQ:NMRA) Will Use Its Cash Wisely [Yahoo! Finance]Yahoo! Finance
NMRA
Earnings
- 3/7/24 - Miss
NMRA
Sec Filings
- 5/7/24 - Form 10-Q
- 5/7/24 - Form 8-K
- 4/25/24 - Form DEFA14A
- NMRA's page on the SEC website